Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 12/20 | 0.77 |
| ▸ | CNR1 | P21554 | 10/20 | 0.77 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.50 |
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.50 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.50 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.50 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.50 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.50 |
| ▸ | HTR2A | P28223 | 1/20 | 0.50 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.50 |
| ▸ | CYP2J2 | P51589 | 1/20 | 0.50 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.50 |
| ▸ | TRPV3 | Q8NET8 | 1/20 | 0.50 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.50 |
| ▸ | TRPV2 | Q9Y5S1 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29353562 | 1.00 | CNR2 (0.77) | CNR2CNR1OPRM1TRPV1TRPA1 | |
| SCHEMBL20911332 | 1.00 | CNR2 (0.77) | CNR2CNR1OPRM1TRPV1TRPA1 | |
| SCHEMBL22916046 | 1.00 | CNR2 (0.77) | CNR2CNR1OPRM1TRPV1TRPA1 | |
| SCHEMBL13214146 | 1.00 | CNR2 (0.77) | CNR2CNR1OPRM1TRPV1TRPA1 | |
| SCHEMBL13214147 | 1.00 | CNR2 (0.77) | CNR2CNR1OPRM1TRPV1TRPA1 | |
| SCHEMBL16124350 | 0.97 | CNR2 (0.72) | CNR2CNR1OPRM1TRPV1TRPA1 | |
| SCHEMBL13214144 | 0.93 | CNR2 (0.66) | CNR2CNR1OPRM1TRPV1TRPA1 | |
| SCHEMBL23076632 | 0.86 | CNR2 (0.66) | CNR2CNR1OPRM1TRPV1TRPA1 | |
| SCHEMBL29400773 | 0.86 | CNR2 (0.66) | CNR2CNR1OPRM1TRPV1TRPA1 | |
| SCHEMBL13214145 | 0.86 | CNR2 (0.66) | CNR2CNR1OPRM1TRPV1TRPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 133 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12036258-B2 | Encapsulated cannabinoid comestible noble metal compositions and products, methods of preparing same | KIFFEN LLC (US) | 2024-07-16 | — | — | US | disclosed |
| US-12036258-B2 | Encapsulated cannabinoid comestible noble metal compositions and products, methods of preparing same | KIFFEN LLC (US) | 2024-07-16 | — | — | US | disclosed |
| US-20240066005-A1 | FORMULATIONS FOR TREATING CLUSTER SYMPTOMS ASSOCIATED WITH AUTISM SPECTRUM DISORDER | ILERA THERAPEUTICS LLC | 2024-02-29 | — | — | US | disclosed |
| US-20240066005-A1 | FORMULATIONS FOR TREATING CLUSTER SYMPTOMS ASSOCIATED WITH AUTISM SPECTRUM DISORDER | ILERA THERAPEUTICS LLC | 2024-02-29 | — | — | US | disclosed |
| US-20240026392-A1 | BIOSYNTHESIS OF CANNABINOIDS AND CANNABINOID PRECURSORS | GINKGO BIOWORKS, INC. (US) | 2024-01-25 | — | — | US | disclosed |
| US-20240026392-A1 | BIOSYNTHESIS OF CANNABINOIDS AND CANNABINOID PRECURSORS | GINKGO BIOWORKS, INC. (US) | 2024-01-25 | — | — | US | disclosed |
| US-20230284578-A1 | EXTRACTS OF CBD AND THC | NEXUS AGRISCIENCE, INC. | 2023-09-14 | — | — | US | disclosed |
| US-11752184-B2 | Bioactive concentrates and uses thereof | PURPLE MUNDO, INC. (US) | 2023-09-12 | — | — | US | disclosed |
| US-11752184-B2 | Bioactive concentrates and uses thereof | PURPLE MUNDO, INC. (US) | 2023-09-12 | — | — | US | disclosed |
| US-20230270763-A1 | METHOD OF TREATING CORONOVIRUS INFECTIONS WITH CANNABINOIDS AND DERIVATIVES | PASCAL BIOSCIENCES INC (CA) | 2023-08-31 | — | — | US | disclosed |
| US-20140271940-A1 | BIOACTIVE CONCENTRATES AND USES THEREOF | SC LABORATORIES, INC. (US) | 2014-09-18 | — | — | US | disclosed |
| US-20140271940-A1 | BIOACTIVE CONCENTRATES AND USES THEREOF | SC LABORATORIES, INC. (US) | 2014-09-18 | — | — | US | disclosed |
| US-8790719-B2 | Phytocannabinoids in the treatment of cancer | GW PHARMA LIMITED (GB) | 2014-07-29 | — | — | US | disclosed |
| US-8790719-B2 | Phytocannabinoids in the treatment of cancer | GW PHARMA LIMITED (GB) | 2014-07-29 | — | — | US | disclosed |
| US-20140065243-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER | SUTTER WEST BAY HOSPITALS | 2014-03-06 | — | — | US | disclosed |
| US-20140065243-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER | SUTTER WEST BAY HOSPITALS | 2014-03-06 | — | — | US | disclosed |
| US-20130059018-A1 | PHYTOCANNABINOIDS IN THE TREATMENT OF CANCER | OTSUKA PHARMACEUTICAL CO., LIMITED (JP) | 2013-03-07 | — | — | US | disclosed |
| US-20130059018-A1 | PHYTOCANNABINOIDS IN THE TREATMENT OF CANCER | OTSUKA PHARMACEUTICAL CO., LIMITED (JP) | 2013-03-07 | — | — | US | disclosed |
| US-20100204312-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER | CALIFORNIA PACIFIC MEDICAL CENTER (US) | 2010-08-12 | — | — | US | disclosed |
| US-20100204312-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER | CALIFORNIA PACIFIC MEDICAL CENTER (US) | 2010-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230270763-A1 | METHOD OF TREATING CORONOVIRUS INFECTIONS WITH CANNABINOIDS AND DERIVATIVES | CNR1, CNR2, SARS1 | CNR2 2/4885CNR1 1/4885OPRM1 90/4885 |
| US-20240066005-A1 | FORMULATIONS FOR TREATING CLUSTER SYMPTOMS ASSOCIATED WITH AUTISM SPECTRUM DISORDER | CNR2, CNR1, GPR18 | CNR2 1/4885CNR1 2/4885OPRM1 847/4885 |
| US-20130059018-A1 | PHYTOCANNABINOIDS IN THE TREATMENT OF CANCER | CNR1, CNR2, LSS | CNR2 2/4885CNR1 1/4885OPRM1 1221/4885 |
| US-20140065243-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER | CNR2, CNR1, JUP | CNR2 1/4885CNR1 2/4885OPRM1 525/4885 |
| US-20100204312-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER | CNR2, CNR1, JUP | CNR2 1/4885CNR1 2/4885OPRM1 525/4885 |
| US-12036258-B2 | Encapsulated cannabinoid comestible noble metal compositions and products, methods of preparing same | CNR2, CNR1, NOTUM | CNR2 1/4885CNR1 2/4885OPRM1 478/4885 |
| US-20140271940-A1 | BIOACTIVE CONCENTRATES AND USES THEREOF | CNR2, CNR1, CDIPT | CNR2 1/4885CNR1 2/4885OPRM1 1024/4885 |
| US-11752184-B2 | Bioactive concentrates and uses thereof | CNR2, CNR1, CDIPT | CNR2 1/4885CNR1 2/4885OPRM1 1024/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.